Pharmazz, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO100%
Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +53.0 months). See all sponsors →
Open Pharmazz, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Normal Saline along with standard treatment NCT04054414 |
P2 | Recruiting | Acute Spinal Cord Injury | 40 | 2026-06 (+72 mo) |
| Normal Saline along with standard treatment NCT05514340 |
P2 | Recruiting | Hypoxic-Ischemic Encephalopathy; Neonatal Asphyxia | 40 | 2026-11 (+25 mo) |
| RESPECT-ETB NCT05691244 |
P3 | Recruiting | Acute Ischemic Stroke; Cerebral Stroke | 514 | 2027-09 (+30 mo) |
| Normal Saline NCT05241067 |
P2 | Not yet recruiting | Acute Respiratory Distress Syndrome (ARDS) | 80 | 2027-10-31 (+53 mo) |
| RESTORE-TBI NCT07861126 |
P3 | Not yet recruiting | Traumatic Brain Injury | 214 | 2028-02 |
| Normal Saline NCT05251181 |
P3 | Not yet recruiting | Hypovolemic Shock | 430 | 2028-10 (+55 mo) |